文献速递血液透析通路

紫杉醇涂层球囊治疗血液透析血管通路狭窄:随机对照试验的系统综述与荟萃分析

Paclitaxel Coated Balloons for Haemodialysis Vascular Access Stenosis: A Systematic Review and Meta-analysis of Randomised Controlled Trials.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2026-04-01

OBJECTIVE: Paclitaxel coated balloons have been used to prevent recurrent stenosis in haemodialysis vascular access. Despite the availability of many randomised controlled trials (RCTs), its effectiveness compared with plain balloon angioplasty remains inconclusive.…

要点

  • 紫杉醇涂层球囊显著降低12个月原发通畅率丢失风险(OR 0.54,95%CI 0.44-0.66)。
  • 每治疗7例可预防1例通路相关再干预(NNT=7,95%CI 5-10)。
  • 证据确定性高,支持强烈推荐用于血管通路狭窄。

核心结论

  • 与普通球囊相比,紫杉醇涂层球囊治疗血管通路狭窄可降低一年内再干预的比值比。
  • 该荟萃分析提供高确定性证据,支持强烈推荐使用紫杉醇涂层球囊治疗血管通路狭窄。

研究设计与样本

  • 主要终点为12个月原发通畅率丢失,使用随机效应模型以比值比汇总治疗效应,注册于PROSPERO(CRD42024502432)。

主要发现

  • 需治疗人数为7(95%CI 5-10)例紫杉醇涂层球囊血管成形术以预防一例通路相关再干预。
  • 敏感性分析显示研究设计、偏倚风险或分析时间点的变化对治疗效果无影响。
  • 亚组分析中,动静脉瘘与移植物、新发与复发性狭窄、或紫杉醇涂层球囊类型之间的治疗效果无显著差异。

关键数值与推荐

  • 证据确定性:原发通畅率丢失为高,血管通路血栓形成和废弃为低。
  • 偏倚风险:5项研究低,19项中等,2项高。

临床怎么用

  • 对于血液透析血管通路狭窄,可优先考虑使用紫杉醇涂层球囊血管成形术以降低一年内再干预风险。
  • 高确定性证据支持将紫杉醇涂层球囊作为治疗血管通路狭窄的强烈推荐选项。

局限性

  • 血管通路血栓形成和废弃的证据确定性低。
  • 多数研究偏倚风险为中等(19项),2项为高偏倚风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Paclitaxel coated balloons have been used to prevent recurrent stenosis in haemodialysis vascular access. Despite the availability of many randomised controlled trials (RCTs), its effectiveness compared with plain balloon angioplasty remains inconclusive. This systematic review and meta-analysis aimed to clarify the effectiveness of paclitaxel coated balloons compared with plain balloon angioplasty for vascular access stenosis based on available randomized controlled trials. DATA SOURCES: Embase.com and Ovid/Medline. REVIEW METHODS: A systematic literature search was performed in Embase.com and Ovid Medline on 02 September 2025 to identify RCTs comparing paclitaxel coated balloons with plain balloons for vascular access stenosis. The primary endpoint was loss of primary patency at 12 months. Risk of bias was assessed with the Cochrane risk of bias tool for randomised trials (RoB 2) and certainty of evidence was assessed with GRADE. The summary treatment effect was estimated by meta-analysis using random effects models with an inverse variance approach based on odds ratios. The meta-analysis was registered with PROSPERO (CRD42024502432) and conducted without external funding. RESULTS: The literature search identified 26 RCTs with 2 930 patients. The overall risk of bias was low in five studies, intermediate in 19 studies, and high in two studies. The odds ratio of primary patency loss after 12 months was 0.54 (95% confidence interval [CI] 0.44 - 0.66; p < .001) in favour of paclitaxel coated balloons, with little between study heterogeneity (I2 10%). This resulted in a number needed to treat of seven (95% CI 5 - 10) paclitaxel coated balloon angioplasties to prevent one access related re-intervention. Sensitivity analyses found no impact of variations in study design, risk of bias, or the time point of analysis on the treatment effect of paclitaxel coated balloons. In subgroup analyses, the treatment effect was not significantly different between arteriovenous fistulas and grafts, new and recurrent stenosis, or paclitaxel coated balloon type. The certainty of evidence was high for loss of primary patency and low for vascular access thrombosis and abandonment. CONCLUSION: Paclitaxel coated balloon angioplasty for vascular access stenosis reduces the odds of re-intervention at one year compared with plain balloon angioplasty. This meta-analysis provides high certainty evidence to support a strong recommendation to use paclitaxel coated balloons when treating vascular access stenosis.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Brans RJB, van Dusseldorp I, Snoeijs MG, et al. Paclitaxel Coated Balloons for Haemodialysis Vascular Access Stenosis: A Systematic Review and Meta-analysis of Randomised Controlled Trials. Eur J Vasc Endovasc Surg. 2026. PMID: 41933692. doi:10.1016/j.ejvs.2026.03.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。